Trial Profile
Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 04 Oct 2019
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Capecitabine; Oxaliplatin
- Indications Gastric cancer
- Focus Therapeutic Use
- 02 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 31 Jul 2015 New trial record